

**SUSTAINED RELEASE N-TERMINALLY TRUNCATED GALECTIN-3 AND
ANTIBODIES TO GALECTIN-3 CARBOHYDRATE LIGANDS FOR USE IN
TREATING CANCER**

ABSTRACT OF THE DISCLOSURE

There is provided a composition for anti-cancer or anti-inflammatory treatment having an effective amount of *N*-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding *N*-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating disease by administering to a patient in need of such treatment an effective amount of *N*-terminally truncated galectin-3, its homologues, antibody to galectin-3 carbohydrate binding sites, or a nucleic acid sequence encoding *N*-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Further, there is provided a disease treatment having an effective amount of *N*-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding *N*-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier.